Abstract：
A key area of therapeutic progress in obstructive hypertrophic cardiomyopathy revolves around the emergence of cardiac myosin inhibitors, of which mavacamten and aficamten represent the first and second molecules. We summarize the key research evidence, including many similarities and potential differences between various clinical trials studying these molecules.
摘要：
梗阻性肥厚型心肌病治疗进展的一个关键领域是围绕心肌肌球蛋白抑制剂的出现，其中mavacanten和aficanten代表第一和第二分子。我们总结了关键的研究证据，包括研究这些分子的各种临床试验之间的许多相似性和潜在差异。
